Fig. 3.

Relationship between annual changes in a TKV and b eGFR over 3 years and percent change in eHTKV-α from baseline at 1 year. Analyses included all patients in TEMPO 3:4 with TKV data available to calculate eHTKV-α at baseline and year 1; tolvaptan-assigned patients were further divided into quartiles (TQ1–TQ4) based on percent change in eHTKV-α from baseline at 1 year. Data presented in top panels are mean ± standard deviation; data presented in bottom panels are LSM ± standard error. *P < 0.001 for LSM difference in annual TKV or eGFR change over 3 years versus placebo; ^#P = 0.007 for LSM difference in annual eGFR change over 3 years versus placebo. eGFR, estimated glomerular filtration rate; eHTKV-α, estimated height-adjusted total kidney volume growth rate; LSM, least squares mean; TKV, total kidney volume; TQ, tolvaptan eHTKV-α quartile